Recent highlights in the synthesis of anti-HCV ribonucleosides

Current Medicinal Chemistry

Volumn 21, Issue 16, 2014, Pages 1843-1860

  Piperno, A ^a   Cordaro, M ^a   Scala, A ^a,b   Iannazzo, D ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR   (Italy)

Author keywords

Antiviral agents; DDA; HCV; NS5B; Nucleosides; Polymerase inhibitors; Universal bases

Indexed keywords

ABT 450; ALISPORIVIR; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; CYTOSINE; DANOPREVIR; DASABUVIR; FALDAPREVIR; FILIBUVIR; GS 9256; LEDIPASVIR; LEVOVIRIN; LOMIBUVIR; MERICITABINE; NONSTRUCTURAL PROTEIN 5B; NUCLEIC ACID BASE; OMBITASVIR; RIBAVIRIN; RIBONUCLEOSIDE; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; URACIL; VANIPREVIR; VEDROPREVIR; ANTIVIRUS AGENT;

DRUG DEVELOPMENT; DRUG RESISTANCE; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; DRUG EFFECTS; HEPACIVIRUS; SYNTHESIS;

ANTIVIRAL AGENTS; HEPACIVIRUS; RIBONUCLEOSIDES;

EID: 84899805690     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131228205935     Document Type: Review

References (76)

1. Initiative for vaccine research: Hepatitis C virus, World Health Organization WHO Program Rep., 2010 February 8, http:// www.cdc.gov/hepatitis/ Statistics/2010Surveillance/index.htm.
2. Zeuzem, S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol., 2008, 5, 610-622.
3. Soriano, V.; Labarga, P.; Fernández-Montero, J.V.; Benito, J.M.; Poveda, E.; Rallon, N.; Sánchez, C.; Vispo, E.; Barreiro, P. The changing face of epatitis C in the new era of direct-acting antivirals. Antiviral Res., 2013, 97, 36-40.
4. Surrazin, C.; Hezode, C.; Zeuzem, S.; Pawlotsky, J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol., 2012, 56, 88-100.
5. Stedman, C. AM. Current prospects for interferon-fre treatment of hepatitis C in 2012. J. Gastroenterol. Hepatol., 2013, 28, 38-45.
6. Sofia, M. J.; Chang, W.; Furman, P.A.; Mosley, R.T.; Ross, B.S. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. J. Med. Chem., 2012, 55, 2481-2253.
7. Lohmann, V.; Korner, F.; Herian, U.; Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol., 1997, 71, 8416-8428.
8. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol., 1999, 6, 937-943.
9. Tan, S.L. Hepatitis C Viruses: Genomes and Molecular Biology; Horizon Bioscience: Norwich, U.K., 2006.
10. Bressanelli, S.; Tomei, L.; Rey, F. A.; De Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol., 2002, 76, 3482-3492.
11. Koch, U.; Narjes, F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr. Top Med. Chem., 2007, 7, 1302-1329.
12. Legrand-Abravanel, F.; Nicot, F.; Izopet, J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs, 2010, 19, 963-975.
13. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology, 2010, 138, 447-462.
14. Carroll, S. S.; Tomassini, J.; Bosserman, B.; Getty, K.; Stahlhut, M.; Eldrup, A. B.; Bhat, B.; Hall, D.; Simcoe, A.; LaFemina, R.; Rutkowski, C. R.; Wolanski, B.; Yang, Z.; Migliaccio, G.; De- Francesco, R.; Kuo, L.C.; MacCoss, M.; Olsen, D. B. Inhibition of hepatitis C virus replication by 2'-modified nucleoside analogs. J. Biol. Chem., 2003, 278, 11979-11984.
15. Gane, E. J.; Roberts, S. K.; Stedman, C. A.; Angus, P. W.; Ritchie, B.; Elston, R.; Ipe, D.; Morcos, P. N.; Baher, L.; Najera, I.; Chu, T.; Lopatin, U.; Berrey, M. M.; Bradford, W.; Laughlin, M.; Shulman, N. S.; Smith, P. F. Oral Combination Therapy with a Nucleoside Polymerase Inhibitor (RG7128) and Danoprevir for Chronic Hepatitis C Genotype 1 Infection (Inform-1): A Randomised, Double- Blind, Placebo-Controlled, Dose-Escalation Trial. Lancet, 2010, 376, 1467-1475.
16. Oeberg, B. Rational design of polymerase inhibitors as antiviral drugs. Antiviral Res., 2006, 71, 90-95.
17. Sabini, E.; Ort, S.; Monnerjahn, C.; Konrad, M.; Lavie, A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat. Struct. Biol., 2003, 10, 513-519.
18. Loakes, D. The application of universal DNA base analogues. Nucleic Acids Res., 2001, 29, 2437-2447.
19. Kronenberger, B.; Zeuzem, S. Current and future treatment options for HCV. Ann. Hepatol., 2009, 8, 103-112.
20. Harki, D. A.; Graci, J. D.; Korneeva, V. S.; Ghosh, S.K.B.; Hong, Z.; Cameron, C. E.; Peterson, B. R. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-D-ribofuranosyl-3- nitropyrrole. Biochemistry, 2002, 41, 9026-9033.
21. Crotty, S.; Maag, D.; Arnold, J. J.; Zhong, W.; Lau, J. Y. N.; Hong, Z.; Andino, R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutage. Nat. Med., 2000, 6, 1375-1379.
22. Liu, W. Y.; Li H. Y.; Zhao, B. X.; Shin D.S.; Lian, S.; Miao, J.Y.; Synthesis of novel ribavirin hydrazone derivatives and antiproliferative activity against A549 lung cancer cells. Carbohyd. Res., 2009, 344, 1270-1275.
23. Tam, R. C.; Lim, C.; Bard, J.; Pai, B. Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. J. Immunol., 1999, 163, 3709-3717.
24. Zhang, P.; Dong, Z. E.; Cleary, T. P. Synthesis of methyl 1-(2,3,5- tri-o-acetyl - l-ribofuranosyl)-1,2,4-triazole-3-carboxylate from Lribose: from a laboratory procedure to a manufacturing process. Org. Process Res. Dev., 2005, 9, 583-592.
25. Suzuki, T.; Moriyama, K.; Otsuka, C.; Loakes, D.; Negishi K. Template properties of mutagenic cytosine analogues in reverse transcription. Nucleic Acids Res., 2006, 34, 226438-226449.
26. Stuyver, L. J.; Whitaker, T. R.; McBrayer, B. I.; Hernandez-Santiago, S.; Lostia, P. M.; Tharnish, M.; Ramesh, C. K.; Chu, R.; Jordan, J., Shi, S.; Rachakonda, K. A.; Watanabe, M. J.; R. F. Schinazi. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother., 2003, 47, 244-254.
27. Barnard, D. L.; Hubbard, V. D.; Burton, J.; Smee, D. F.; Morrey, J. D.; Otto, M. J.; Sidwell R. S. Inhibition of severe acute respiratory syndrome-associated corona-virus (SARSCoV) by calpain inhibitors and DN4-hydroxycytidine. Antivir. Chem. Chemother., 2004, 15, 15-22.
28. Hernandez-Santiago, B.I.; Beltran, T.; Stuyver, L.; Chu, C. K.; Schinazi, R. F. Metabolism of the Anti-Hepatitis C Virus Nucleoside D-N4-Hydroxycytidine in Different Liver Cells. Antimicrob. Agents Chemother., 2004, 48, 4636-4642.
29. Felczak, K.; Miazga, A.; Pozaski, J.; Bretner, m.; Kulikowski, T.; Dzik, J. M; Goos, B.; Zieliski, Z.; Ciela, J.; Rode, W. 5-Substituted N4-hydroxy-2-deoxycytidines and their 5-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity. J. Med. Chem., 2000, 43, 4647-4656.
30. Wempen, I.; Miller, N.; Falco, E.A.; Fox, J.J. Nucleosides. XLVII. Syntheses of some N4-substituted derivatives of 1-Darabinofuranosylcytosine and -5-fluorocytosine. J. Med. Chem., 1968, 11, 144-148.
31. Lu, J.; Li, N-S, Koo, S.C.; Piccirilli J.A. Efficient synthesis of N4- methyl- and N4-hydroxycytidine phosphoramidites. Synthesis, 2010, 16, 2708-2712.
32. Lee, H-R.; Kim, W. H.; Park, A-Y.; Kang, J-A; Chun, P.; Bae, J.H.; Jeong, L.S.; Moon, H.R. Synthesis of pyrimidine analog of fluoroneplanocin A as potential anti HCV agent. Nucleic Acids Symposium Serie, 2008, 52, 607-608.
33. Hollecker1, L.; Choo, H.; Chong, Y.; Chu, C.K.; Lostia, S.; McBrayer, T.R.; Stuyver, L.J.; Mason, J.C.; Du, J.; Rachakonda, S.; Shi, J.; Schinazi, R. F.; Watanabe, K.A. Synthesis of - enantiomers of N4-hydroxy-3'-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. Antivir. Chem. Chemother., 2004, 14, 43-55.
34. Olsen, D.B.; Eldrup, A.B.; Bartholomew, L.; Bhat, B.; Bosserman, M.R.; Ceccacci, A.; Colwell, L.F.; Fay, F.J.; Flores, O.A.; Getty, K.L.; Grobler J.A.; LaFemina, R.L.; Markel, E.J.; Migliaccio, G.; Prhavc, M.; Stahlhut, M.W.; Tomassini, J.E.; MacCoss, M.; Hazuda, D.J.; Carroll, S.S. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellents pharmacokinetic properties. Antimicrob. Agents Chemother., 2004, 48, 3944-3953
35. Wu R.; Smidansky, E.D.; Suk Oh, H.; Takhampunya R.; Padmanabhan, R.; Cameron, C.E.; Peterson B. R. Synthesis of a 6-methyl- 7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses. J. Med. Chem., 2010, 53, 7958-7966.
36. Nau, P.; Pohl, R.; Votruba, I.; Dubák, P.; Hajdúch, M.; Ameral, R.; Birku, G.; Wang, T.; Ray, A. S.; Mackman, R.; Cihlar, T.; Hocek, M. 6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. J. Med. Chem., 2010, 53, 460-470.
37. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y.H.; Das, A.R.; Chakraborty, S.K.; Hong, S. C.; Tsay, S-C.; Hsu, M-H.; Hwu J.R. Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates. J. Med. Chem., 2009, 52, 1486-1490.
38. Hwu, J.R.; Singha, R.; Hong, S. C.; Chang, Y.H.; Das, A.R.; Vliegen, I.; De Clercq, E.; Neyts, J. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res., 2008, 77, 157-162.
39. Hwu, J.R.; Lin, S-Y.; Tsay, S-C.; De Clercq, E.; Leyssen, P.; Neyts, J. Coumarin-purine ribofuranoside conjugates as new agents against hepatitis C virus. J. Med. Chem., 2011, 54, 2114-2126.
40. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol., 1999, 6, 937-943.
41. Ferrari, E.; Wright-Minogue, J.; Fang, J. W. S.; Baroudy, B. M.; Lau, J. Y. N.; Hong, Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol., 1999, 73, 1649-165.
42. Gordon, C. P.; Keller, P. A. Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem., 2005, 48, 1-18.
43. O'Farrell, D.; Trowbridge, R.; Rowlands, D.; Jager, J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol., 2003, 326, 1025-1035.
44. Brieba, L. G.; Sousa, R. Roles of Y639 and H784 in ribose discrimination by T7 RNAP. Biochemistry, 2000, 39, 919-923.
45. Bressanelli, S., Tomei, L., Rey, F. A., De Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol., 2002, 76, 3482-349.
46. Klumpp, K.; Kalayanov, G.; Ma, H.; Le Pogam S.; Leveque, V.; Jiang, W-R.; Inocencio, N.; De Witte, A.; Rajyaguru S.; Tai, E.; Chanda, S.; Irwin M.R.; Sund, C.; Winqist, A.; Maltseva, T.; Eriksson, S.; Usova, E.; Smith, M.; Alker, A.; Najera, I.; Cammack, N.; Martin, J.; Johansson, N.G.; Smith, D.B. 2'-Deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-hydroxyl groups. J. Biol. Chem., 2008, 283, 2167-2175.
47. Carroll, S.S.; Olsen, D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets, 2006, 6, 17-29.
48. Eldrup, A. B.; Allerson, C. R.; Bennett, C. F.; Bera, S.; Bhat, B.; Bhat, N.; Bosserman, M. R.; Brooks, J.; Burlein, C.; Carroll, S.S.; Dan Cook, P.; Getty, K.L.; MacCoss, M.; McMasters, D.R.; Olsen, D.B.; Prakash, T. P.; Prhavc, M.; Song, Q.; Tomassini, J. E.; Xia, J. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem., 2004, 47, 2283-2295.
49. Eldrup, A. B.; Prhavc, M.; Brooks, J.; Bhat, B.; Prakash, T. P.; Song, Q.; Bera, S.; Bhat, N.; Dande, P.; Dan Cook, P.; Bennett, C. F.; Carroll, S.S.; Ball, R.G.; Bosserman, M.; Burlein, C.; Colwell L.F.; Fay, J.F.; Flores, O.A.; Getty, K.; LaFemina, R.L.; Leone, J.; MacCoss, M.; McMasters, D.R.; Tomassini, J. E.; Von Langen, D.; Wolanski, B.; Olsen, D.B. Structure-activity relationship of heterobase-modified 2?-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem., 2004, 47, 5284-5297.
50. Carroll, S.S; Ludmerer, S.; Handt, L.; Koeplinger, K.; Zhang, N.R.; Graham, D.; Davies, M-E; MacCoss, M.; Hazuda, D.; Olsen, D.B. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother., 2009, 53, 926-934.
51. Olsen, D.B.; Davies, M.E.; Handt, L.; Koeplinger, K.; Zhang, R.N.; Ludmerer, S.W.; Graham, D.; Liverton, N.; MacCoss, M.; Hazuda, D.; Carroll, S.S. Sustained viral response in a hepatitis C virusinfected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob. Agents Chemother., 2011, 55, 937-939.
52. Franchetti, P.; Cappellacci, L.; Marchetti, S.; Trincavelli, L.; Martini, C.; Mazzoni, M.R.; Lucacchini, A.; Grifantini, M. 2'-C-methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J. Med. Chem., 1998, 41, 1708-1715.
53. Wolfe, S.R.; Harry-O'Kuru, R.E. A concise synthesis of 2'-Cmethylribonucleosides. Tetrahedron Lett., 1995, 36, 7611-7614.
54. Azuma, A.; Nakajima, Y.; Nishizono, N.; Minakawa, N.; Suzuki, M.; Hanaoka, K.; Kobayashi, T.; Tanaka, M.; Sasaki, T.; Matauda, A. Nucleosides and Nucleotides. 122. 2'-C-cyano-2'-deoxy-1-Darabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J. Med. Chem., 1993, 36, 4183-4189.
55. Li, N-S.; Piccirilli, J.A. Efficient synthesis of 2'-C - methylguanosine. J. Org. Chem., 2006, 71, 4018-4020.
56. Pierra, C.; Benzaria, S.; Amador, A.; Moussa, A.; Mathie, S.; Storer, R.; Gosselin, G. NM-283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids, 2005, 24, 767-770.
57. Clark, J.L.; Hollecker, L.; Mason J.C.; Stuyver L.J.; Tharnish P.M.; Lostia, S.; McBrayer T.R.; Schinazi, R.F.; Watanabe, K.A.; Otto, M.J.; Furman, P.A.; Stec., W.J.; Patterson, S.E.; Pankiewicz K.W. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-Cmethylcytidine, a potent inhibitor of hepatitis C Virus Replication. J. Med. Chem., 2005, 48, 5504-5508.
58. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao,J.; Mathie, S.; Moussa, A.; Bridges, E.G.; Standring, D.N.; Somadossi, J.P.; Storer, R.; Gosselin, G. Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrugs of the Potent Anti-HCV Agent 2'-C-Methylcytidine. J. Med. Chem., 2006, 49, 6614-6620.
59. Standring, D.N.; Lanford, R.; Wright, T.; Chung, R.T.; Bichko, V.; Cretton-Scott, E.; Pan Zhou, X.; Bergelson, S.; Qu, L.; Tausek, M.; Bridges, E.; Moussa, A.; Storer, R.; Pierra, C.; Benzaria, S.; Gosselin, G.; La Colla, P.; Sommadossi, J.P. NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1)infection in the chimpanzee. J. Hepatol., 2003, 38, 3.
60. De Francesco, R.; Carfí, A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependentRNA polymerase of the hepatitis C. Adv. Drug Deliv. Rev., 2007, 59, 1242-1262
61. Clark, J. L.; Mason, J.C.; Hobbs, A.J.; Hollecker, L.; Schinazi, R. F. Synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses. J. Carbohydr. Chem., 2006, 25, 461-470.
62. Mayes B. A.; Moussa, A. Process for preparing a synthetic intermediate for preparation of branched nucleosides. PCT Int. Appl., WO 2007075876A2 20070705. July 7, 2007.
63. Wang, P.; Chun, B. K.; Rachakonda, S., Du, J.; Khan, N.; Shi, J.; Stec, W.; Cleary, D.; Ross, B. S.; Sofia, M. J. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J. Org. Chem., 2009, 74, 6819-6824.
64. Gane, E. J.; Roberts, S. K.; Stedman, C. A.; Angus, P. W.; Ritchie, B.; Elston, R.; Ipe, D.; Morcos, P. N.; Baher, L.; Najera, I.; Chu, T.; Lopatin, U.; Berrey, M. M.; Bradford, W.; Laughlin, M.; Shulman, N. S.; Smith, P. F. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (Inform-1): a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet, 2010, 376, 1467-1475.
65. Murakami, E.; Niu, C.; Bao, H.; Micolochick Steuer, H. M.; Whitaker, T.; Nachman, T.; Sofia, M. J.; Wang, P.; Otto, M. J.; Furman, P. A. The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother., 2008, 52, 458-464.
66. Smith, D.B.; Martin, J.A.; Klumpp, K.; Baker, S.J.; Blomgren, P.A.; Devos, R.; Granycome, C.; Hang, J.; Hobbs, C. J.; Jiang, W.-R.; Laxton, C.; Le, P.S.; Leveque, V.; Ma, H., Maile, G.; Merrett, J. H.; Pichota, A.; Sarma, K.; Smith, M.; Swallow, S.; Symons, J.; Vesey, D.; Najera, I.; Cammack, N. Design, synthesis, and antiviral properties of 4-substituted ribonucleosides as inhibitors of Hepatitis C Virus replication: the discovery of R1479. Bioorg. Med. Chem. Lett., 2007, 17, 2570-2576.
67. Klumpp, K.; Leveque, V.; Le Pogam, S.; Ma, H.; Jiang, W. R.; Kang, H.; Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, K.; Smith, D. B.; Heindl, D.; Hobbs, C. J.; Merrett, J. H.; Symons, J.; Cammack, N.; Martin, J. A.; Devos, R.; Najera, I. The novel nucleoside analog R1479 (4-azidocytidine) is a potent inhibitor of NS5B-Dependent RNA: synthesis and hepatitis C Virus replication in cell culture. J. Biol. Chem., 2006, 281, 3793-3799.
68. Brandl, M.; Wu, X.; Holper, M.; Hong, L.; Jia, Z.; Birudaraj, R.; Reddy, M.; Alfredson, T.; Tran, T.; Larrabee, S.; Hadig, X.; Sarma, K.; Washington, C.; Hill, G.; Smith, D. B. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug. Dev. Ind. Pharm., 2008, 34, 683-669.
69. Divakar, K. J.; Reese, C. B. 4-(1,2,4-Triazol-1-yl)-and 4-(3-nitrol, 2,4-triazol-l-yl)-l-(-D-2,3,5-tri-Oacetylarabinofuranosyl) pyrimidin-2-(lH)- ones. Valuable intermediates in the synthesis of derivatives of 1 -(-D-arabinofuranosy1) cytosine (Ara-C). J. Chem. Soc., Perkin Trans. 1, 1982, 1171-1176.
70. Piperno, A.; Chiacchio, M. A.; Romeo, R.; Iannazzo, D. Synthesis and biological activity of phosphonated nucleosides: Part 1. Furanose, carbocyclic and heterocyclic analogues. Curr. Med. Chem., 2006, 13, 3675-3695.
71. Gunaga, P.; Moon, H, R.; Choi, W. J.; Shin, D. H.; Park, J. G.; Jeong, L. S. Recent advances in 4'-thionucleosides as potential antiviral and antitumor agents. Curr. Med. Chem., 2004, 11, 2585-2637
72. Lee, J.A.; Kim, H. O.; Tosh, D. K.; Moon, H. R.; Kim, S.; Jeong, L.S. Stereoselective synthesis of 2'-C-methyl-cyclopropyl-fused carbanucleosides as potential anti-HCV Agents. Org. Lett., 2006, 8, 5081-5083.
73. Gadthula, S.; Rawal, R. K.; Sharon, A.; Wu, D.; Korba, B.; Chu, C. K. Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4R,5S,6R,7R)-4-(6-amino-9H-purin-9-yl)-7(hydroxy methyl-spiro[2.4]heptane-5,6- diol against Hepatitis C Virus. Bioorg. Med. Chem. Lett., 2011, 21, 3982-3985.
74. Jeong, L. S.; Tosh, D. K.; Kim, H. O.; Wang, T.; Hou, X.; Yun, H. S.; Kwon, Y.; Lee, S. K.; Choi, J.; Zhao, L. X. First synthesis of 4'-Selenonucleosides showing unusual Southern conformation. Org. Lett., 2008, 10, 209-212.
75. Chiacchio, U.; Borrello, L.; Crispino, L., Rescifina, A.; Merino, P.; Macchi, B.; Balestrieri, E.; Mastino, A.; Piperno, A.; Romeo, G. Stereoselective synthesis and biological evaluations of novel 3'-deoxy-4'-azaribonucleosides as inhibitors of Hepatitis C Virus RNA replication. J. Med. Chem., 2009, 52, 4054-4057.
76. Piperno, A.; Carnovale, C.; Giofrè, S.V; Iannazzo, D. Hydrozirconation of four-, five-, six-and seven-membered N-alkoxycarbonyl lactams to lactamols. Tetrahedron Lett., 2011, 52, 6880-6882.